Vayamed Cannakits®: Innovative cannabis formulation kits enable new forms of application for an expanded therapy spectrum – experienced therapists sought for clinical support survey

The special formulation sets are available in three variants for the standardized production of nasal spray emulsion, vaginal suppositories and rectal suppositories (cannabis extracts are not included): Vayamed Cannakit® Nasal Spray is designed to support rapid onset of action through absorption at the nasal mucosa and offers a simple alternative to oral or inhaled dosing that can be used discreetly in everyday life. Vayamed Cannakit® vaginal suppositories are intended to enable new therapeutic approaches in women’s health: Vaginal application offers an alternative to oral or inhaled dosing and also has the potential to open up new therapeutic areas such as the treatment of endometriosis symptoms, PMS or inflammation. Vayamed Cannakit® rectal suppositories are designed to offer an alternative when oral or inhaled forms of dosage are more difficult, for example for patients who are terminally ill.

First market version available – experienced therapists sought for clinical support survey

“After almost two years of development, we are very proud to be the first medical cannabis company in Germany to offer these alternative dosages in cannabis therapy. The new therapy options of the Vayamed Cannakits® are intended to benefit especially those patient groups for whom no optimal cannabis therapy has been possible so far due to a lack of alternative dosage forms, for example in palliative care or women’s health,” says Thimo V. Schmitt-Lord, Director New Markets & Innovation in the medical sector of Berlin-based Sanity Group, to which Vayamed belongs.

The first version of the Vayamed Cannakits®, which is now available in pharmacies, is specifically aimed at physicians with cannabis therapy experience, who would like to use the product on selected patients in individual therapy trials and thus contribute to further product development and casuistry developments.
Doctors who would like to receive more information and participate in a standardized evaluation of the use of the product in clinical practice can contact Vayamed at
Further information about the Vayamed Cannakits® is also available online at

About Vayamed
Vayamed specializes in the development and distribution of innovative cannabinoid-based medicinal products for the European market and is committed to making medicinal cannabis widely available to physicians, pharmacists and patients. To this end, Vayamed works with an established network of international partners. Vayamed is part of the Sanity Group, a health and life science company based in Berlin, Germany, dedicated to the medical and healthcare use of cannabinoids. For more information, visit and

Image: Vayamed / Sanity Group (c)

Sanity Medical Vayamed

Vayamed and telemedicine pioneer Telaleaf launch exclusive partnership

Telaleaf, a telemedicine company transforming the access and delivery of medical cannabis care to patients, and Berlin-based medical cannabis brand Vayamed are pleased to announce a strategic partnership to strengthening the quality of telemedicine services in cannabis therapy in Germany through premium quality virtual care and to improve access, in line with Vayamed’s brand vision: “Medicine from Nature. Customized for Patients”. Vayamed and Telaleaf are driven by the vision that telemedicine will continue to move healthcare delivery from clinic to home, and will become the standard in cannabis-based medicine. Doctor visits to consult about Vayamed products and treatment options are planned as well as further programs in the field of talent support and further training at leading medical faculties nationwide. 

“The importance of telemedicine in the German healthcare system will continue to grow. It offers many benefits for doctors, patients and the healthcare system, for example better access and treatment quality, qualified trainings, and improved health insurance reimbursement levels through special training offers for doctors. Together with Telaleaf, we want to improve therapies with medical cannabis in Germany through the utilization of telemedicine”, said Thimo V. Schmitt-Lord, Director New Markets & Innovation at Vayamed.

“In order to fully realize the vision of cannabis-based medicine as the advanced, alternative medicinal modality it has proven to be, Telaleaf has entirely reimagined the cannabis healthcare delivery model such that all necessary medical services, tools and resources come together for patients and doctors under one unified field. Our joint mission with Vayamed is to drive better health outcomes for patients with personalized virtual care that is sustained by expert-led medicinal cannabis training and education,” said Telaleaf CEO Gavin Treanor.

Telaleaf collaborates with leading experts such as Prof. Kirsten Müller-Vahl, M.D., and Franjo Grothenhermen, M.D., and the medical cannabis training for participating doctors is provided at the highest educational level in cooperation with Dresden International University.


About Vayamed 
Medical cannabis specialist Vayamed, a brand of Berlin-based health and life science company Sanity Group, specializes in the development and distribution of innovative cannabinoid-based medicinal products for the European market and, as a reliable provider, is committed to making medical cannabis accessible to doctors, pharmacists and patients. 

About Telaleaf
Telaleaf is a telemedicine company transforming the delivery of cannabis care by connecting patients to expert doctors, trained in cannabis-based medicine, who conduct virtual medical visits and provide personalized treatment plans. Our aim is to improve patient outcomes, by improving the patient experience with high quality treatment, ease of access and expert-led training to doctors, for the most advanced virtual care in cannabis medicine.